» Articles » PMID: 38414466

Down-regulation of MiR-133a-3p Protects Lung Tissue Against Sepsis-induced Acute Respiratory Distress Syndrome by Up-regulating SIRT1

Overview
Journal Arch Med Sci
Specialty General Medicine
Date 2024 Feb 28
PMID 38414466
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: MicroRNA-133a-3p (miR-133a-3p) is a potential gene regulator having an important role in the process of inflammation and lung injury. The present work studied the role of miR-133a-3p in sepsis-mediated acute respiratory distress syndrome (ARDS) and the mechanism involved.

Material And Methods: C57BL/6 mice were selected for the study. Protein expression of Bcl-2, cleaved caspase-3 and Bax was assessed by western blot analysis. Expression of mRNA was assessed by RT-PCR. Effects of inflammation were studied by myeloperoxidase (MPO) activity. Quantification of albumin was done by measuring the albumin conjugated with Evan's blue. The alveolar macrophages were separated from the lungs of mice by the bronchoalveolar lavage procedure and were submitted to sepsis challenge ; the macrophages were treated with lipopolysaccharide (LPS).

Results: Treatment of LPS resulted in upregulation of miR-133a-3p in alveolar macrophages. Suppression of miR-133a-3p halted the over-expression of inflammatory cytokines in macrophages and caused remission of histopathologic changes. The ARDS lungs showed a decrease in levels of proinflammatory cytokines and an increase in levels of apoptotic protein, establishing the protective role for miR-133a-3p. The results suggested sirtuin 1 (SIRT1) as a potential target of miR-133a-3p in the macrophages, also showing that expression of SIRT1 was inversely associated with expression of miR-133a-3p. The protective effect of miR-133a-3p down-regulation in LPS-mediated alveolar macrophages and sepsis-induced ARDS could be corrected by a SIRT1 inhibitor.

Conclusions: Down-regulation of miR-133a-3p may exert a protective effect on lung tissue against sepsis-mediated ARDS by up-regulating the levels of SIRT1 via suppressing the inflammatory response and inhibiting the cellular apoptosis in lung tissues.

References
1.
Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T . Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002; 12(9):735-9. DOI: 10.1016/s0960-9822(02)00809-6. View

2.
Lavu S, Boss O, Elliott P, Lambert P . Sirtuins--novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov. 2008; 7(10):841-53. DOI: 10.1038/nrd2665. View

3.
Yang S, Wright J, Bauter M, Seweryniak K, Kode A, Rahman I . Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. Am J Physiol Lung Cell Mol Physiol. 2006; 292(2):L567-76. DOI: 10.1152/ajplung.00308.2006. View

4.
Koutsoulidou A, Mastroyiannopoulos N, Furling D, Uney J, Phylactou L . Expression of miR-1, miR-133a, miR-133b and miR-206 increases during development of human skeletal muscle. BMC Dev Biol. 2011; 11:34. PMC: 3132729. DOI: 10.1186/1471-213X-11-34. View

5.
Zhang J, Lee S, Shannon S, Gao B, Chen W, Chen A . The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest. 2009; 119(10):3048-58. PMC: 2752073. DOI: 10.1172/JCI38902. View